Company profile
BioMarin Pharmaceutical Inc.
NASDAQ: BMRN · Healthcare · Biotechnology
#80 of 1,422 Healthcare companies by revenue59th-percentile growth
EA Score
85AFH 85DQ 92GM 71SS 91
v0.1 · 65/100 weight · provisional
↑ market scale, filing timeliness · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$3.2B
Rev growth YoY (TTM)
+9.9%
Net income (FY)
$348.9M
Employees
3,221
as of 2026-08-06
Market cap
$11.6B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.2B$3.2B2025
Net income$348.9M$348.9M2025
Operating income$409.5M$409.5M2025
Total assets$7.6B$7.6B2025
Liabilities$1.5B$1.5B2025
Equity$6.1B$6.1B2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product98%
Royalty And Other2%
By geography
Not disclosed.
The read
What is BioMarin Pharmaceutical Inc.’s revenue?
BioMarin Pharmaceutical Inc. booked $3.2B in FY2025 revenue, growing 13% year over year — about the middle of the pack among Healthcare companies we track, at a 10.8% net margin.
Peers · Healthcare
Acadia Healthcare Company, Inc.67BSurgery Partners, Inc.71BAdaptHealth Corp.67BBrookdale Senior Living Inc.73BUnited Therapeutics Corporation92AAstrana Health, Inc.75B+Neighbors
Marin →Key facts
CEOAlexander Hardy
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Rafael, CA
ExchangeNASDAQ: BMRN
Employees3,221
IPO date1999-07-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.